Meet The DermaSensor Team
Operational Team

Cody Simmons
Chief Executive Officer

Ryan Freiden
Chief Operations Officer

Gary Slatko
Chief Medical Officer

Kiran Chatha, MD
Associate Medical Director, Clinical and Medical Affairs

Jacqueline Barberena
Senior Director of Marketing

Justin Frazier
Senior Director of Clinical Operations

Ruth Stachura
National Sales Director

Jordan Whittle
Sales Area Director

Frank Rios
AREA SALES DIRECTOR

Robert Langley
Manager of Inside Sales

Jeriah Hercules
Associate Manager, Sales Operations
Discover what other practitioners are saying.
Our study indicates that DermaSensor’s ESS device has the potential to enhance the detection of skin malignancies in the primary care setting. This technology not only improved PCPs’ sensitivity for lesion referral but also significantly increased their confidence, both of which are particularly important for non-specialists

Department of Dermatology Clinical Trials Unit
The dermatology community and I have been advocating the use of dermatoscopes for decades with primary care physicians, but with limited success given the significant and repeated training that is needed. I'm thrilled that this new automated device is now available for these physicians with training time of just a few minutes.
Dr. Harold Rabinovitz, MDBoard Certified Dermatologist, Professor of Dermatology, Medical College of Georgia
As skin cancer rates continue to rise, the need for accurate and efficient skin cancer detection in primary care is increasingly important. These studies have shown the ESS device benefits physicians, and it is also a non-invasive, easy-to-use solution for instantaneously evaluating suspicious lesions.

for the DERM-SUCCESS clinical utility study
In primary care, we don't want to miss a chance to catch skin cancer as soon as possible, but skin lesions can be challenging to evaluate. DermaSensor is fast and easy to use and adds objectivity and confidence to these clinical decisions.
Todd Thames MD MHABoard Certified Family Medicine Physician, Instructor, Trinity University
As a dermatologist that trained PCPs at One Medical for years, I think this device will be transformational for PCPs correctly managing suspicious lesions.

University of California, San Francisco
The DermaSensor device will be a great service to provide to my patients who are concerned about skin lesions, and an invaluable tool to help me decide how to manage their care."

In sunny Miami, skin cancer is a real concern. I'm excited to use a new non-invasive, FDA-cleared, AI-powered device to improve detection accuracy and provide peace of mind for high-risk patients

As a PCP I can incorporate this FDA cleared device on patients during their skin assessment. But where I really see a tremendous value for this tool is during our massages and facials. Our team is trained to identify suspicious lesions and having DermaSensor gives us greater confidence in be able to help our clients

Google said it was cancer but let’s assess your lesion now with our new age AI assisted skin cancer screening device to provide real time objective results

" I am super excited to announce that we have a new device called DermaSensor at Montgomery Medical. I originally had the opportunity to work with DermaSensor through a clinical trial at Frontier Clinical Research. Now that it is FDA-cleared, we are excited to be one of the first PCP offices to offer this new technology that uses light to help us assess suspicious skin lesions. It is painless and only takes a few seconds to give us an immediate result

At Sanctum Med + Wellness, we deliver exceptional healthcare services prioritizing patient well-being and addressing every aspect of their health. Adding the DermaSensor device to our comprehensive range of services further underscores our commitment to staying at the forefront of medical innovation

We are proud to be the first medical practice in the northern half of the United States to offer this innovative solution, and we are confident it will make a profound impact on our approach to skin health
